文献速递核素与放射性配体治疗肿瘤 PET/CT

长轴视野(LAFOV)PET/CT 用于钇-90 放射性栓塞治疗后剂量学的评估:与常规 SPECT 显像的比较研究

Evaluation of long axial field-of-view (LAFOV) PET/CT for post-treatment dosimetry in Yttrium-90 radioembolization of liver tumors: a comparative study with conventional SPECT imaging.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2024-12-28

该回顾性分析纳入 32 例接受选择性内放射治疗(SIRT)的肝肿瘤患者,比较 LAFOV PET/CT 与 SPECT/CT 治疗后剂量学。器官级剂量学显示 PET 与 SPECT 肿瘤剂量相近,但基于体素的 PET 肿瘤剂量显著低于计划 SPECT,且 D90 显著低于 SPECT;PET 测得肺分流分数和肺平均吸收剂量也显著低于计划 SPECT。作者认为 LAFOV PET 可直接测量治疗后肺剂量和肿瘤剂量,但当前体素级剂量学工具对 LAFOV PET 似乎不准确。

要点

  • LAFOV PET/CT 可在 SIRT 治疗后直接测量肺剂量和肿瘤剂量,与计划剂量相关性好。
  • 基于体素的 LAFOV PET 肿瘤剂量显著低于计划 SPECT 剂量(中位 152.5 Gy vs 276.0 Gy,p<0.00001)。
  • PET 测得肺分流分数和肺平均吸收剂量显著低于计划 SPECT,作者认为需改进体素级 90Y 剂量学工具。

核心结论

  • LAFOV PET 能够直接测量治疗后肺剂量和肿瘤剂量,且与计划治疗剂量相关性好。
  • 然而,当前基于体素的肿瘤剂量学对 LAFOV PET 似乎不准确,且基于剂量体积直方图的指标也显著低估实际递送剂量。
  • 因此,需要改进的剂量学工具来实现可靠的体素级 90Y 剂量学,以充分利用 LAFOV PET 扫描仪的灵敏度和空间分辨率。

研究设计与样本

  • 回顾性分析,共纳入 32 例患者(中位年龄 71 岁,IQR 14),患有肝细胞癌、胆管癌或肝转移。
  • 所有患者接受 SIRT,治疗后扫描同时使用 SPECT/CT 和 LAFOV Biograph Quadra PET/CT 采集,采集时间 20 分钟。
  • 治疗后剂量学(肿瘤、全肝和肺吸收剂量)采用器官级(Simplicit90Y)和体素级(HERMIA Dosimetry,半蒙特卡罗算法)两种方法。
  • 肺分流分数(LSF)采用体素级方法测量,并与计划值比较。

主要发现

  • 基于器官级剂量学,计划 SPECT(SPECTpre)、治疗后 SPECT(SPECTpost)和 PET(PETpost)的中位肿瘤剂量分别为 276.0 Gy(200.0-330.0 Gy)、232.0 Gy(158.5-303.5 Gy)和 267.5 Gy(182.5-370.8 Gy)。
  • 基于体素级的 PETpost 中位肿瘤剂量为 152.5 Gy(94.8-223.8 Gy),显著小于计划 SPECTpre(p<0.00001)。
  • 肿瘤体积 90% 处的中位吸收剂量(D90)在 SPECTpost 显著高于 PETpost:123.5 Gy(81.5-180.0)vs 30.5 Gy(11.3-106.3),p<0.00001。
  • PETpost 测得的 LSF 显著低于计划 SPECTpre:0.89%(0.4-1.3%)vs 2.3%(1.5-3.6%),p<0.0001。
  • PETpost 测得的中位肺平均吸收剂量(LMD)显著低于计划 SPECTpre:1.2 Gy(0.6-2.3)vs 2.5 Gy(1.4-4.7),p<0.0001。

关键数值与推荐

  • 器官级剂量学中,计划 SPECTpre 中位肿瘤剂量 276.0 Gy(200.0-330.0 Gy),SPECTpost 232.0 Gy(158.5-303.5 Gy),PETpost 267.5 Gy(182.5-370.8 Gy)。
  • 体素级 PETpost 中位肿瘤剂量 152.5 Gy(94.8-223.8 Gy),显著低于计划 SPECTpre(p<0.00001)。
  • D90 在 SPECTpost 为 123.5 Gy(81.5-180.0),在 PETpost 为 30.5 Gy(11.3-106.3),p<0.00001。
  • LSF 在 PETpost 为 0.89%(0.4-1.3%),在计划 SPECTpre 为 2.3%(1.5-3.6%),p<0.0001。
  • LMD 在 PETpost 为 1.2 Gy(0.6-2.3),在计划 SPECTpre 为 2.5 Gy(1.4-4.7),p<0.0001。

临床怎么用

  • LAFOV PET 可用于 SIRT 治疗后直接测量肺剂量和肿瘤剂量,并与计划剂量比较。
  • 作者认为,当前基于体素的肿瘤剂量学对 LAFOV PET 似乎不准确,且基于剂量体积直方图的指标显著低估递送剂量。
  • 作者指出,需要改进的剂量学工具来实现可靠的体素级 90Y 剂量学,以利用 LAFOV PET 扫描仪的灵敏度和空间分辨率。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Long axial field-of-view (LAFOV) positron emission tomography/computed tomography (PET/CT) scanners enable high sensitivity and wide anatomical coverage. Therefore, they seem ideal to perform post-selective internal radiation therapy (SIRT) 90Y scans, which are needed, to confirm that the dose is delivered to the tumors and that healthy organs are spared. However, it is unclear to what extent the use of LAFOV PET is feasible and which dosimetry approaches results in accurate measurements. METHODS: In this retrospective analysis, a total number of 32 patients was included (median age 71, IQR 14), which had hepatocellular carcinoma, cholangiocarcinoma, or liver metastases. All patients underwent SIRT, and the post-therapy scan was acquired on a single photon emission computed tomography/computed tomography (SPECT/CT) and a LAFOV Biograph Quadra PET/CT with a 20-minute acquisition time. Post-treatment dosimetry, regarding the tumor, whole-liver and lung (LMD) absorbed dose was done using an organ-wise (Simplicit90Y) and a voxel-wise approach (HERMIA Dosimetry) which used a semi-Monte Carlo algorithm. The lung shunt fraction (LSF) was also measured using the voxel-wise approach and compared to the planned. RESULTS: The planning, post-treatment SPECT and PET (SPECTpre, SPECTpost, PETpost) median tumor doses based on the organ-wise dosimetry were 276.0 Gy (200.0-330.0 Gy), 232.0 Gy (158.5-303.5 Gy) and 267.5 Gy (182.5-370.8 Gy). In contrast, the median voxel-wise PETpost dose was significantly smaller than the planned SPECTpre (152.5 Gy (94.8-223.8 Gy); p < 0.00001). Moreover, the median tumor absorbed dose at 90% (D90) of the tumor volume was significantly higher in SPECTpost compared with PETpost (123.5 Gy; 81.5-180.0 vs. 30.5 Gy; 11.3-106.3; p < 0.00001). The PETpost measured LSF was significantly lower compared to the planned SPECTpre (0.89%; 0.4-1.3% vs. 2.3%; 1.5-3.6%; p < 0.0001). Similarly, the measured PETpost median LMD was considerably lower to the planned SPECTpre (1.2 Gy; 0.6-2.3 vs. 2.5 Gy; 1.4-4.7; p < 0.0001). CONCLUSION: LAFOV PET enabled the direct measurement of post therapy lung dose and tumor doses that correlated well with the planned treatment doses. However, current voxel-wise-based tumor dosimetry seems to be inaccurate for LAFOV PET. In addition, dose volume histogram-based metrics also significantly underestimate the delivered dose. Therefore, improved dosimetry tools are needed for reliable voxel-wise 90Y dosimetry to leverage the sensitivity and spatial resolution of LAFOV PET scanners.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Zeimpekis KG, Sari H, Gözlügöl N, et al. Evaluation of long axial field-of-view (LAFOV) PET/CT for post-treatment dosimetry in Yttrium-90 radioembolization of liver tumors: a comparative study with conventional SPECT imaging. Eur J Nucl Med Mol Imaging. 2024. PMID: 39730786. doi:10.1007/s00259-024-07034-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。